Plant Virus–NK Agonist Combination for Tumor Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells evade immune response through immunosuppressive mechanisms, posing challenges in recruiting and activating Natural Killer (NK) cells within the tumor microenvironment.
Innovation Solution
A composition comprising a plant virus (e.g., Cowpea chlorotic mottle virus, Cowpea mosaic virus, or Sesbania mosaic virus) combined with an NK cell agonist (such as an anti-4-1BB antibody) is administered to recruit and activate NK cells, potentially overcoming immunosuppression and enhancing their tumor-killing capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NK cells are recruited to the tumor microenvironment, then tumor-killing capability is improved, but immunosuppressive mechanisms of cancer cells prevent effective activation and function
Solution Approach 1:
The patent uses plant virus particles (CCMV, CPMV, PhMV, or SeMV) as intermediary carriers that deliver NK cell activating ligands to the tumor microenvironment. These virus particles serve as mediators between the administered NK cell agonists and the tumor cells, enabling NK cell activation while overcoming immunosuppressive barriers. The virus particles facilitate the interaction between NK cells and tumor cells by presenting activating signals in the tumor microenvironment.
Solution Approach 2:
The patent modifies the functional parameters of NK cells by combining them with specific plant virus particles that have been engineered to express NK cell activating ligands. This combination changes the activation state and functional capacity of NK cells, transforming them from a potentially suppressed state to an activated state capable of effective tumor killing. The parameter change involves altering the biological activity and responsiveness of NK cells through viral vector-mediated signal delivery.
2Reliability
If NK cell agonists are administered to activate NK cells, then tumor-killing capability is improved, but recruitment of NK cells to the tumor microenvironment remains insufficient
Solution Approach 1:
Plant virus particles serve as intermediary delivery vehicles that facilitate NK cell recruitment to the tumor microenvironment. The virus particles carry activating ligands that bind to NK cell receptors, creating a signal that attracts and activates NK cells. This intermediary mechanism solves the recruitment problem by providing a targeted delivery system that guides NK cells to the tumor site.
Solution Approach 2:
The patent employs preliminary action by pre-administering the plant virus particles containing NK cell activating ligands before or concomitantly with NK cell infusion. This preliminary delivery of activating signals prepares the tumor microenvironment to be receptive to NK cells, creating a permissive environment that enhances subsequent NK cell recruitment and activation.
3Reliability
If combination therapy with plant virus and NK cell agonist is used, then tumor burden is significantly decreased, but complexity of treatment regimen increases
Solution Approach 1:
The patent merges the plant virus particle system with NK cell agonist therapy into a unified combination treatment. This combining approach integrates two therapeutic mechanisms (viral delivery and immunostimulation) into a single coordinated regimen that synergistically enhances tumor killing. The merging of these therapies creates a more potent anti-tumor effect than either therapy alone.
Solution Approach 2:
The treatment regimen functions as a composite therapeutic system combining viral vectors and immunological agents. This composite approach integrates different therapeutic modalities (viral therapy and immunotherapy) into a unified treatment strategy that leverages the complementary mechanisms of both components to achieve superior anti-tumor efficacy.
Data Source
AI summary
This disclosure provides compositions and combinations for treating cancer. The compositions or combinations comprise a plant virus and a natural killer (NK) cell agonist.